SPH Notice – The Capital Group Companies, Inc.

100080615/3821103.1
Disclosure of movement of 1% or more in substantial holding
or change in nature of relevant interest, or both
Sections 277 and 278, Financial Markets Conduct Act 2013
Note: This form must be completed in accordance with the instructions at the end of the
form.
To New Zealand Stock Exchange & Australian Stock Exchange
and
To Fisher & Paykel Healthcare Corp.
Relevant event being disclosed: a movement of 1% or more in the substantial holding
Date of relevant event: 28 July 2020
Date this disclosure made: 29 July 2020
Date last disclosure made: 29 July 2020
Substantial product holder(s) giving disclosure
Full name(s): The Capital Group Companies, Inc.
Summary of substantial holding
Class of quoted voting products: Ordinary Shares (FPH)
Summary for The Capital Group Companies, Inc.
For this disclosure,—
(a) total number held in class: 30,810,713
(b) total in class: 574,902,659
(c) total percentage held in class: 5.3592%
For last disclosure,—
(a) total number held in class: 37,000,052
(b) total in class: 573,995,023
(c) total percentage held in class: 6.4460%
Details of transactions and events giving rise to relevant event
Details of the transactions or other events requiring disclosure: On 28 July 2020, a total of -
1,171,555 shares were sold on-market. See details below.
Asset Description Activity
Transaction
Type
Currenc
y
Price Shares
FISHER & PAYKEL HEALTHCARE CORP 24-Jul-20 Sell NZD 35.1300 1,137,915
FISHER & PAYKEL HEALTHCARE CORP 24-Jul-20 Sell NZD 35.4638 33,640

100080615/3821103.1
Details after relevant event
Details for The Capital Group Companies, Inc.
The Capital Group Companies, Inc. (“CGC”) is the parent company of Capital Research and
Management Company (“CRMC”). CRMC is a U.S.-based investment management
company that manages the American Funds family of mutual funds. CRMC manages
equity assets for various investment companies through three divisions, Capital Research
Global Investors, Capital International Investors and Capital World Investors. CRMC in
turn is the parent company of Capital Group International, Inc. (“CGII”), which in turn is
the parent company of five investment management companies (“CGII management
companies”): Capital Guardian Trust Company, Capital International, Inc., Capital
International Limited, Capital International Sàrl and Capital International K.K. The CGII
management companies primarily serve as investment managers to institutional clients.
Neither CGC nor any of its affiliates own shares of your company for its own account.
Rather, the shares reported on this Notification are owned by accounts under the
discretionary investment management of one or more of the investment management
companies described above.
Nature of relevant interest(s): Non-beneficial owner of securities
For that relevant interest,—
(a) number held in class: 30,810,713
(b) percentage held in class: 5.3592%
(c) current registered holder(s):
Nominee Name Sum of Shares Held
H.S.B.C. Bank P.L.C. London 29,182
JP Morgan Bank London 55,631
JP Morgan Bank Luxembourg 5,840
JPMorgan Chase Bank 16,149,549
Northern Trust Company Chicago 104,298
Northern Trust Company London 9,587
State Street Bank North Quincy 13,609,974
State Street Trust Canada 801,000
The Bank of New York Mellon 45,652
Total Shares Held 30,810,713

(d) registered holder(s) once transfers are registered: unknown
For a derivative relevant interest, also—
(a) type of derivative: not applicable
(b) details of derivative: not applicable
(c) parties to the derivative: not applicable

100080615/3821103.1
(d) if the substantial product holder is not a party to the derivative, the nature of the
relevant interest in the derivative: not applicable
Additional information
Address(es) of substantial product holder(s): 333 South Hope Street, 55
th
Floor, Los
Angeles, California, 90071, USA
Contact details: Danielle Harris, Telephone #: ++213.615.0469, E-mail:
GRGroup@capgroup.com.
Certification
I, Danielle Harris, certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make this disclosure
by all persons for whom it is made.